IL 8 Serum Level Estimation in the Iraqi Myloproliferative Neoplasm Patients with and without JAK2-V617F Mutation

Abstract

Introduction: Myeloproliferative neoplasm (MPN) is a long-term blood disease that has an excess production of mature hematopoietic pluripotent stem cells (HPSC) in the bone marrow. The Iraqi cancer registry announced that Chronic Myeloproliferative disorders in male has 0.62% incidence rate and 0.36, in female Chronic Myeloproliferative disorders 45case 0.31% and incidence rate 0.24. The JAK2-V617F mutation is approximately 70% presented in the myeloproliferative neoplasm cases. This is a somatic mutation that concern changing of the amino acid valine to phenylalanine at codon region 617 (that’s why it’s called JAK2-V617F) presented in the pseudo kinase domain. JAK2-V617F mutation is 50% to 70% in Essential Thrombocythemia (ET), 40% to 50% in Primary Myelofibrosis (PMF), and 95% in Polycythemia Vera (PV). IL-8 elevated level in MPNs has a major part in the presence of symptoms